Related Experiment Videos
Current concepts of hemostasis: implications for therapy
Harold R Roberts1, Dougald M Monroe, Miguel A Escobar
1Division of Hematology/Oncology, Carolina Cardiovascular Biology Center, University of North Carolina School of Medicine, Chapel Hill 27599-7035, USA. hrr@med.unc.edu
Anesthesiology
|April 28, 2004
Summary
The revised coagulation model impacts treating bleeding and clotting disorders. Anesthesiologists can manage surgical clotting issues with factor concentrates, anticoagulants, and recombinant factor VIIa for severe bleeding.
Area of Science:
- Anesthesiology
- Hematology
- Pharmacology
Background:
- The revised model of coagulation offers new therapeutic strategies.
- Coagulation management is critical for perioperative care.
- Hemorrhagic and thrombotic disorders require tailored treatment approaches.
Purpose of the Study:
- To explore the implications of the revised coagulation model for managing hemorrhagic and thrombotic disorders.
- To highlight the relevance of coagulation management for anesthesiologists in surgical settings.
- To review current therapeutic strategies for clotting abnormalities.
Main Methods:
- Review of current literature on coagulation models and therapies.
- Analysis of management guidelines for perioperative patients.
- Discussion of specific treatments including clotting factor concentrates, anticoagulants, and recombinant factor VIIa.
Main Results:
- Hereditary and acquired coagulation factor deficiencies are manageable with factor concentrates.
- Guidelines exist for perioperative management of patients on anticoagulants.
- Recombinant factor VIIa serves as an off-label hemostatic agent for refractory bleeding.
Conclusions:
- The revised coagulation model provides a framework for optimizing therapy in bleeding and thrombotic disorders.
- Anesthesiologists play a key role in managing perioperative clotting abnormalities.
- Current therapies, including factor replacement and recombinant factor VIIa, offer effective management options.